This site is intended for Healthcare Professionals outside the U.S.

It looks like you are using an older version of Internet Explorer which is not supported. We advise that you update your browser to the latest version of Microsoft Edge, or consider using other browsers such as Chrome, Firefox or Safari.

Home > Dosing and Administration

Patient adherence not impacted by BID dosing

Average Dose
Line Break

Dosing overview

 

Recommended Tasigna starting dose
Recommended Tasigna starting dose
Line Break

Reference: 1. Habucky K, Duverger B, Kreft R, Kozlovsky V. TASIGNA® (nilotinib) 50 mg, 150 mg and 200 mg hard capsules core data sheet, version 1.8. West Sussex, United Kingdom: Novartis Europharm Limited; 2016:1-54.

This is an international website for TASIGNA® (nilotinib) and is intended for healthcare professionals outside the U.S.
If you are a U.S. resident, please click here or on the U.S. Residents link on this page.